Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01957709 · ClinicalTrials.gov registry record · Early Phase 1
Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
A Early Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT01957709: Clinical Trial Early Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
NCT01957709 is a Early Phase 1 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 8 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01957709, a Early Phase 1 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the effect of recombinant interferon gamma on tissue in treating patients with soft tissue sarcoma. Interferon gamma may interfere with the growth of tumor cells.
Primary Outcome
It would be highly relevant to observe marked increase macrophages (effect size \> 2.5). Four patients gives over 90% power to detect such a large increase with a two-tailed alpha of 0.05.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Recombinant Interferon Gamma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-09-25 |
| Est. Completion | 2018-06-01 |
| Phase | Early Phase 1 |
Why NCT01957709 stopped before completion
NCT01957709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01957709 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01957709 about?
NCT01957709 is a clinical study titled "Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma". This pilot clinical trial studies the effect of recombinant interferon gamma on tissue in treating patients with soft tissue sarcoma. Interferon gamma may interfere with the growth of tumor cells.
What is the current status of trial NCT01957709?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2013-09-25. Estimated completion is 2018-06-01.
What interventions are being tested in trial NCT01957709?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Recombinant Interferon Gamma (BIOLOGICAL).
Who is sponsoring clinical trial NCT01957709?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01957709's enrollment target sits among peer trials
8 1782nd of 2000 higher than 176 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI